This Cooperative Agreement award from the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,245,116 to Emory University to enhance cervical cancer screening and treatment services for women living with HIV in Kenya. The project aims to adapt and test evidence-based implementation strategies to increase cervical cancer screening rates and linkage to care among this high-risk population. Key activities include: Engaging...
This federal Project Grant award of $368,070 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The primary awardee, Trustees of Boston University, will conduct qualitative interviews with women with HIV and healthcare providers to understand factors affecting follow-up and treatment for cervical cancer....
The National Cancer Institute (NCI) awarded a $629,068 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Albert Einstein College of Medicine to conduct an implementation science study on leveraging Project ECHO for improved cervical cancer screening in Ethiopia. The study aims to explore and address challenges to cervical cancer screening among women living with HIV by integrating point-of-care HPV self-sampling into routine HIV care at...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will fund a hybrid type III effectiveness-implementation trial to test best practices for deploying a cervical cancer screen and treat approach utilizing self-collected HPV DNA testing in HIV care and treatment facilities in Mozambique. The primary outcome is to screen women and treat those who test positive, with secondary outcomes focused on...
The National Cancer Institute (NCI) awarded a $1,837,497 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to New York University (NYU) for the "KUPEWA: Optimizing Strategies to Implement Provider Recommendation of HPV Vaccination for Adolescent Girls and Young Women with HIV in Malawi" project. The 5-year project aims to: (A) identify optimal implementation strategies to increase clinician recommendation of HPV vaccination for girls and young...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $381,487 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Maryland, Baltimore (UMB) to assess the implementation and outcomes of introducing long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women at high risk of HIV acquisition in Zambia. The study, titled "Scaling Comprehensively Access to Long-Acting for...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $706,365 to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to address the high burden of cervical cancer in this population by integrating preventive screening and treatment services through a bundle of strategies including...
This federal Cooperative Agreement award, with a total funding amount of $511,959, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The purpose of the award is to develop and evaluate implementation strategies to integrate a home-based HPV self-sampling and communication intervention (HOPE) into the healthcare system in Ghana to increase cervical cancer screening among women living with HIV. The project, titled "The...
This $393,142 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support a study to explore synergies in pharmacy-based delivery of pre-exposure prophylaxis (PrEP) and contraception for adolescent girls and young women (AGYW) in Kenya. The study will be conducted by the University of Washington and involve a cluster randomized clinical trial at 20 pharmacies in...
This federal Project Grant award of $728,006 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a 2x2 factorial randomized controlled trial (RCT) to optimize treatment of co-occurring smoking and unhealthy alcohol use among people with HIV (PWH) in Nairobi, Kenya. The study will compare an intensive behavioral counseling program with and without alcohol-referent content, as well as the smoking cessation medication cytisine...
KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH - KEMRI-PHRD CLINICAL TRIAL SITE FOR CASCADE NETWORK 'CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV PROJECT SUMMARY/ABSTRACT: CERVICAL CANCER IS THE LEADING CAUSE OF CANCER-RELATED DEATHS IN WOMEN IN EASTERN AND SOUTHERN AFRICA, THE REGIONS WITH THE HIGHEST BURDEN OF HIV INFECTION GLOBALLY. (1) IN EAST AFRICA, 2020 ESTIMATES REPORTED THAT A QUARTER OF NEW CERVICAL CANCER CASES COULD BE ATTRIBUTED TO HIV INFECTION. (2) CERVICAL CANCER MORBIDITY AND MORTALITY REFLECTS GLOBAL INEQUITY WITH THE MOST VULNERABLE POPULATIONS CARRYING THE GREATEST DISEASE BURDEN. THE KEMRI-CCR-PHRD RESEARCH CLINIC IN PARTNERSHIP WITH LVCT HEALTH DHIBITI HIV/TB PEPFAR/CDC PROGRAM (SUPPORTING 31,800 PLHIV IN CENTRAL REGION OF KENYA) HAVE ORGANIZED A CONSORTIUM OF HIV AND CERVICAL CANCER CLINICAL, RESEARCH AND PROGRAM EXPERTS AND THROUGH THIS APPLICATION PROPOSE TO JOIN THE UG1 AS A NETWORK CLINICAL TRIAL SITE AND IMPLEMENT HIV/CERVICAL CANCER PREVENTION STUDIES. WE PROPOSE TO IMPLEMENT THE UG1 NETWORK STUDIES AT THREE SELECTED HIV CARE CLINICS BASED IN RURAL URBAN PUBLIC HOSPITALS IN KIAMBU COUNTY (THIKA LEVEL 5, RUIRU LEVEL 4, IGEGANIA LEVEL 4 HOSPITALS). THE THREE SELECTED HOSPITALS ARE PART OF TEN REPRODUCTIVE HEALTH (RH) CLINICS IMPLEMENTING THE 'TIBA' STUDY (5R01CA258590-02 MUGO), AN IMPLEMENTATION SCIENCE STUDY EVALUATING THE IMPLEMENTATION OF SCREEN AND TREAT (SAT) + SINGLE VISIT APPROACH (SVA) WITH THERMAL ABLATION (TA). WE HAVE CAPACITY AND RESOURCES TO PARTICIPATE IN ALL FOUR PROPOSED FOCAL UG1 RESEARCH AREAS; INCREASE SCREENING UPTAKE, IMPROVE MANAGEMENT OF SCREEN POSITIVES, FACILITATE PRECANCER TREATMENT ACCESS AND OPTIMIZE PRECANCER TREATMENTS FOR CERVICAL CANCER PREVENTION FOR WLWH. THROUGH PARTNERSHIP WITH LVCT HEALTH DHIBITI HIV/TB CDC/PEPFAR FUNDED CARE PROGRAM AND LEVERAGING ON- GOING IMPLEMENTATION SCIENCE STUDIES CONDUCTED IN THE SELECTED PUBLIC HEALTH FACILITIES, WE PROPOSE IN AIM 1, TO PROVIDE INFRASTRUCTURE TO RECRUIT, ENROLL AND RETAIN WLWH TO THE UG1 NETWORK STUDIES. THE THREE SELECTED FACILITIES HAVE AN ESTIMATE OF 4,000 WLWH ENROLLED IN THE HIV/TB CARE CLINICS, WITH THE OPTION TO EXPAND TO 10,000 BY INCORPORATING THE TEN TIBA STUDY CLINICS. IN AIM 2, WE PROPOSE TO INTERFACE WITH THE UG1 RESEARCH BASES AND U24 NETWORK COORDINATING CENTER DURING CONCEPT AND PROTOCOL DEVELOPMENT TO PROVIDE INSIGHTS AND INPUT ON ISSUES PERTAINING TO CLINICAL SIGNIFICANCE, STUDY FEASIBILITY, IMPLEMENTATION AND CONTRIBUTE TOWARDS RAISING UP RELEVANT PRIORITY RESEARCH QUESTIONS. KEMRI-CCR-PHRD CO-PIS HAVE PARTICIPATED IN MULTIPLE MULTISITE CLINICAL TRIALS AND HAVE BEEN PROTOCOL CHAIRS ON NETWORK STUDIES. IN AIM 3, WE PROPOSE TO PROVIDE ON-SITE OPERATIONAL LEADERSHIP FOR THE SUCCESSFUL CONDUCT OF THE NETWORK CLINICAL TRIALS. THE KEMRI-CCR-PHRD RESEARCH UNIT HAS 16 YEARS' EXPERIENCE CONDUCTING CLINICAL RESEARCH AND HAS WELL TESTED STANDARDIZED SYSTEMS AND MATERIALS FOR IMPLEMENTATION OF RESEARCH IN ACCORDANCE WITH INTERNATIONAL REGULATORY REQUIREMENTS.